When I went to the FDA's Web site today I was surprised to see on the homepage a link to a letter written by Commissioner Dr. Peggy Hamburg. It's addressed to "Dear Healthcare Professional" aka a "Dear Doctor letter." That's a common type of communication from the agency and/or companies to the medical community, usually when they've got bad news to pass along about a drug or device. It's pretty rare for the commish to write one.    Read More

Stocks continued to rise on Tuesday, continuing Monday's rally. Two bulls, Michelle Picard, fund manager at HighMark Geneva Growth, and Mike O’Rourke, chief market strategist at BTIG Bass Trading, said the markets have further room to run.    Read More

Many analysts, lobbyists and industry executives have been saying for months that healthcare reform would probably end up being a net positive for the drug companies.    Read More

On Saturday, the House backed a health care bill that would expand coverage to nearly all Americans and bar insurance practices such as refusing to cover people with pre-existing medical conditions. How should investors be positioned? Bob Phillips, managing partner at Spectrum Management Group and Robert Zagunis, co-portfolio manager at Jensen Investment Management shared their insights.    Read More

This weekend, the US House of Representatives passed its version of health care reform and now awaits a version from the Senate.  The debate has been heating up since earlier this summer when President Obama was pushing for legislation before the summer recess.  Here are the biggest S&P Health Care gainers and losers over while the debate has waged on.   Read More

It appears that Washington is about to enact sweeping legislation that will be the greatest shift in public policy in decades. Yes, we can bemoan the lack of a completely private enterprise driven system but the reality is Big Brother is here and he's not going away. Without a doubt there will be implications for investors that need to be considered; and it's not all bad news from an investment perspective.   Read More

A healthcare reform vote in the House tomorrow; why are HMOs trading up? You'd think the likelihood of a vote—and better than even chance of passage—would be a negative for HMOs.    Read More

Stacy and Clinton definitely had nothing to do with it, but Sanofi-Pasteur (the vaccines division of Sanofi-Aventis) greets visitors with a "What Not To Wear" brochure.    Read More

I am not a Trekkie. In fact, sci-fi and fantasy are two of of my least favorite genres. But the Vulcan salutation was one of the first things I thought of when I went to the facelifted Merck Web site this morning to link to and print the press release about the new Merck.    Read More

How can you invest along the same principles as Warren Buffett? James Altucher, managing director of Formula Capital, shared his insights.    Read More